Pharmaceutical Newswire
1 - Elan Corporation plc Announces Pricing of New 2016 Senior Notes
DUBLIN-(Business Wire)-September 29, 2009 - Elan Corporation, plc ("Elan") today announced the pricing of the offering of US$625 million aggregate principal amount of senior notes due 2016 (“New Notes”) by its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance...
2 - Idaho Technology Expands Its High Resolution Melting Patent Portfolio
SALT LAKE CITY-(Business Wire)-September 29, 2009 - Idaho Technology’s patent portfolio continues to grow as the U.S. Patent and Trademark Office granted the company U.S. Patent No. 7,582,429 relating to methods of performing genetic analysis in the presence of a double-stranded nucleic acid...
3 - JMP Securities Healthcare Conference to Be Held in New York
SAN FRANCISCO-(Business Wire)-September 29, 2009 - JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that JMP Securities will host the fourth annual JMP Securities Healthcare Focus Conference at The New York Palace hotel in New York on Monday...
4 - Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Cases
BRIDGEWATER, N.J.-(Business Wire)-September 29, 2009 - Cordis Corporation (“Cordis”) announced today that it has reached an agreement with Boston Scientific (“Boston”) resolving its Palmaz infringement suit relating to Boston’s NIR stent, settling several other cardiology-related cases...
5 - MannKind to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
VALENCIA, Calif.-(Business Wire)-September 29, 2009 - MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Tuesday...
6 - AZBio Announces Recipients of 2009 Awards
PHOENIX-(Business Wire)-September 29, 2009 - AZBio (Arizona BioIndustry Association) announced the winner of the association's annual awards, which were presented at the 2009 AZBio Awards Dinner, the largest annual gathering of Arizona's bioscience community, on Thursday, September 24th at the...
7 - Taro Files Lawsuit against Sun in U.S. Federal Court
HAWTHORNE, N.Y.-(Business Wire)-September 29, 2009 - Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) filed a lawsuit today against Sun Pharmaceutical Industries Ltd. and certain of its affiliates (collectively, “Sun”) in the United States District Court...
8 - Celera to Webcast Presentation at JMP Securities 2009 Healthcare Conference
ALAMEDA, Calif.-(Business Wire)-September 29, 2009 - Celera Corporation (NASDAQ:CRA) announced today that it will webcast its presentation at the JMP Securities 2009 Healthcare conference on Tuesday, October 6, 2009. The live webcast is scheduled to begin at 10:00 am ET. Ugo DeBlasi, Chief Financial...
9 - SATAI Announces $1.045 Million Emerging Technology Fund Investment in Azaya Therapeutics, Inc.
SAN ANTONIO-(Business Wire)-September 29, 2009 - SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the...
10 - SeraCare Life Sciences Awarded Multiple Contracts from the CDC and NIH to Support HIV Research and the Accuracy of HIV Testing
MILFORD, Mass.-(Business Wire)-September 29, 2009 - SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has been awarded two new contracts from the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) and that a third existing contract has been...
11 - Flu Vaccination Program is Smart Business – Shortage of Vaccine is Predicted
OMAHA, Neb.-(Business Wire)-September 29, 2009 - Omaha-based Total Wellness, a leading provider of corporate health and wellness services, encourages employers – both large and small – to follow recommendations made by the Center for Disease Control and Prevention (CDC), which encourages...
12 - Intelligent Enterprise Solutions, Inc., is Hosting 3rd qPCR Symposium USA on 9-12 November at Millbrae, CA
SANTA CLARA, Calif.-(Business Wire)-September 29, 2009 - qPCR (Real-time quantitative PCR) has rapidly developed as the prime technology to detect and quantify nucleic acids in complex samples. It is used in the life science industry, healthcare, diagnostics, forensics, food, feed, agriculture, air...
13 - Girindus Not Affected by Solvay's Decision to Sell Pharmaceuticals Sector
BERGISCH GLADBACH, Germany & CINCINNATI, Ohio-(Business Wire)-September 29, 2009 - Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay's decision to sell its...
14 - Parker Waichman Alonso LLP Files Suit Against Bayer Corporation on Behalf of Woman Injured by the Yaz Birth Control Pill
GREAT NECK, N.Y.-(Business Wire)-September 29, 2009 - Parker Waichman Alonso LLP filed suit on behalf of a woman who suffered bilateral pulmonary emboli and deep vein thrombosis after taking the Yaz birth control pill. Yaz, as well as its precursor, Yasmin, have been associated with life-threatening...
15 - Personalized, Gene-Based Risk Testing For Lung Cancer Gives New Tool To Help Smokers Quit
PHILADELPHIA-(Business Wire)-September 29, 2009 - Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd. The...
16 - Amerinet Economic Solutions Series Focuses on Revenue Cycle Efficiencies
ST. LOUIS-(Business Wire)-September 29, 2009 - Amerinet, a leading healthcare group purchasing organization is highlighting strategies to enhance the revenue cycle as part of its continuing Economic Solutions series, an initiative focused on keeping members proactively engaged with current...
17 - Clinical Data, Inc. to Present at the JMP Securities Healthcare Focus Conference
NEWTON, Mass.-(Business Wire)-September 29, 2009 - Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the Fourth Annual JMP Securities Healthcare Focus Conference. Clinical Data's presentation...
18 - Cubist Pharmaceuticals Announces Enhanced Careers Section of Corporate Website
LEXINGTON, Mass.-(Business Wire)-September 29, 2009 - Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is pleased to announce the re-launch of its corporate website and the introduction of the newly created Careers section. Our goal is to enhance the job seekers’ experience with both active and...
19 - RegeneRx’s Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
BETHESDA, Md.-(Business Wire)-September 29, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an...
20 - Atlantic General Hospital and Rite Aid Bring In-Store Health Care Clinics to Ocean Pines and Pocomoke City, Maryland, and Millsboro, Delaware
CAMP HILL, Pa.-(Business Wire)-September 29, 2009 - Rite Aid Corporation (NYSE:RAD) and Atlantic General Hospital and Health System today announced an agreement to open Atlantic ImmediCare clinics inside three Rite Aid stores in Ocean Pines and Pocomoke City, Maryland, and Millsboro, Delaware...
21 - Study Shows AFRESA® Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients
VIENNA-(Business Wire)-September 29, 2009 - AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting...
22 - Court Rules in Favor of Bard in Class Action Lawsuit
MURRAY HILL, N.J.-(Business Wire)-September 29, 2009 - C. R. Bard, Inc. (NYSE: BCR) today announced that the U.S. District Court, Eastern District of Missouri, has granted Bard's summary judgment motion and dismissed with prejudice all counts in the previously-disclosed class action lawsuit entitled...
23 - LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients
HØRSHOLM, Denmark-(Business Wire)-September 29, 2009 - LifeCycle Pharma A/S (CSE:LCP) today announced positive results from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug...
24 - Research and Markets: The Value of Serbia's Pharmaceuticals and Healthcare Market Is Expected to Top RSD113.77 (US$1.69bn) in 2013
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets Galenika Zdravlje Actavis Jugoremedija For more information visit http://www.researchandmarkets.com/research/0b4072/serbia_pharmaceuti.
25 - Top Life Sciences Attorney to Join Intrexon as Chief Legal Officer
BLACKSBURG, Va.-(Business Wire)-September 29, 2009 - Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the appointment of Asher M. Rubin as Executive Vice President, Chief Legal Officer...
26 - Research and Markets: Oman's Over-The-Counter (OTC) Products Are Expected to Increase Their Share of the Total Pharmaceuticals and Healthcare Market From 11% in 2008 To 13% in 2013
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets For more information visit http://www.researchandmarkets.com/research/57c330/oman_pharmaceutica.
27 - New APCER Pharma Solutions, Inc. Webinar Offers Pharmaceutical Companies Actionable Advice on Managing 2010 FDA Drug Safety Initiatives
PRINCETON, N.J.-(Business Wire)-September 29, 2009 - APCER Pharma Solutions, Inc.’s (“APCER”) important new webinar will feature an enlightening approach to help prepare pharmaceutical companies for 2010 FDA drug safety and pharmacovigilance initiatives. The event is free of charge. Title...
28 - Luminex Corporation Hosts Seventh Annual Planet xMAP Europe
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it will host Planet xMAP Europe 2009, its annual European multiplexing technology symposium, October 7-8, 2009, at Beurs van Berlage in Amsterdam. The program for Planet xMAP Europe 2009...
29 - Weitz & Luxenberg News: Court Affirms $4.5 Million Award in Vioxx Trial and Dismisses Appeal by Merck & Co. on Preemption after Wyeth ruling
NEW YORK-(Business Wire)-September 29, 2009 - Weitz & Luxenberg P.C. (www.weitzlux.com) would like to inform the public of a ruling of the New Jersey Supreme Court issued on May 7, 2009, but just released this week, which dismissed an appeal by Merck & Co. in the case McDarby v. Merck. The...
30 - Bio Japan 2009: The Biggest Biotechnology Event in Japan.
YOKOHAMA, Japan-(Business Wire)-September 29, 2009 - We would like to thank you sincerely for your understanding and ongoing cooperation for BioJapn. With your wholehearted support, BioJapan has been progressing successfully in both its contents and scale every year. This year, we are aiming to...
31 - Pluristem Therapeutics Has Been Selected to Present at The Israeli Presidential Conference 2009: Facing Tomorrow, Based on the Company’s Proprietary Technology and the Potential to Shape The Future of the Stem Cell Industry
HAIFA, Israel-(Business Wire)-September 29, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced it has been selected as one of the Israeli innovators in the stem cell field to present at The Israeli Presidential Conference 2009: Facing Tomorrow – Tomorrow's Industries...
32 - Innovex and Healthcare at Home Announce Joint Venture
BRACKNELL, UK & BURTON-UPON-TRENT, UK-(Business Wire)-September 29, 2009 - Innovex, a Quintiles company, and Healthcare at Home today announced that they have agreed to form an innovative healthcare joint venture in Europe, named Healthcare at Home Europe. Healthcare at Home Europe, a separate...
33 - Vitae Receives $8 Million Payment from Boehringer Ingelheim for Achievement of 11beta-HSD-1 Program Milestone
FORT WASHINGTON, Pa.-(Business Wire)-September 29, 2009 - Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned an $8 million milestone payment from Boehringer Ingelheim for achievement of a performance milestone in their...
34 - Humco® Significantly Increases Production of Cherry Syrup for Emergency Pharmacy Compounding of Oral Suspension of Tamiflu® Capsules amidst Extraordinary Demand
TEXARKANA, Texas-(Business Wire)-September 29, 2009 - Humco Holding Group, Inc. today announced it has significantly increased its October production of Humco® Cherry Syrup for use in the emergency compounding by pharmacists of an oral suspension from Tamiflu® capsules, intended for children and...
35 - Seattle Genetics to Present at JMP Securities Healthcare Focus Conference
BOTHELL, Wash.-(Business Wire)-September 29, 2009 - Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that company management will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Monday, October 5, 2009, at 8:30 a.m. Eastern Time. The conference is being held at The...
36 - Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma
BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug...
37 - Pfizer Receives Approval from China’s Ministry of Commerce for Pending Wyeth Acquisition
NEW YORK-(Business Wire)-September 29, 2009 - Pfizer Inc (NYSE:PFE) today announced that China’s Ministry of Commerce has approved the company’s pending acquisition of Wyeth. The Ministry’s decision includes Pfizer’s commitment to divest certain animal health assets in China. “We are...
38 - Research and Markets: This Essential Report on India's Pharmacy Retail Market is Now Available
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets has announced the addition of the "Pharmacy Retail Market - India" report to their offering. The pharmacy retail market is valued at INR 216 bn in 2009 and estimated to reach INR 432 bn in 2011. The market is fragmented and dominated...
39 - Novelos Therapeutics Announces $1 Million NIH Grant to MGH to Study NOV-002 and NOV-205 In Animal Models of Radiation-Induced Lung Injury
NEWTON, Mass.-(Business Wire)-September 29, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded...
40 - Research and Markets: Slovenia Pharmaceuticals and Healthcare Report Q4 2009 - Now Available
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets For more information visit http://www.researchandmarkets.com/research/ff3d70/slovenia_pharmaceu
41 - Walgreens Launches National Initiative for 90-Day Prescriptions at Community Pharmacies
DEERFIELD, Ill.-(Business Wire)-September 29, 2009 - Walgreens (NYSE:WAG)(NASDAQ:WAG) today launched a broad initiative for 90-day prescriptions that promotes delivery of maintenance and chronic care medication through its national network of more than 7,000 community pharmacies and employer...
42 - Computable Genomix Announces Contest For Genomics Researchers
MEMPHIS, Tenn.-(Business Wire)-September 29, 2009 - Memphis-based Computable Genomix today announced it will launch a contest on Oct. 1, 2009, to coincide with the release of GeneIndexer, the company’s next-generation Web-based text-mining tool. Publish or Perish will award a $10,000 grant to each...
43 - SAIC-Frederick and Roche Enter into a Research Collaboration on Technology Advancements for Cancer Gene Sequencing
MADISON, Wis.-(Business Wire)-September 29, 2009 - National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (NYSE: SAI), and Roche Applied Science, a division of Roche Diagnostics Corporation (SWX:RO) (SWX:ROG) (Pink...
44 - Synta Pharmaceuticals Initiates Fourth Trial of STA-9090, a Novel Synthetic Small Molecule Hsp90 Inhibitor
LEXINGTON, Mass.-(Business Wire)-September 29, 2009 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical...
45 - pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien® Study
WATERTOWN, Mass.-(Business Wire)-September 29, 2009 - pSivida Corp (NASDAQ: PSDV)(ASX: PVA), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today...
46 - Acrux Announces Successful AXIRON™ Phase III Trial Results
NEW YORK-(Business Wire)-September 29, 2009 - Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with testosterone deficiency (hypogonadism), across 26 sites in six countries. AXIRON™ is applied to the...
47 - Walgreen Co. Reports Fourth Quarter 2009 Earnings of 44 Cents Per Diluted Share; Results Include 3 Cents Per Diluted Share of Restructuring Costs
DEERFIELD, Ill.-(Business Wire)-September 29, 2009 - Walgreens (NYSE:WAG)(NASDAQ:WAG): Fourth quarter sales increase 7.6 percent to record $15.7 billion; fiscal 2009 sales reach record $63.3 billion Cash flow from operations for fiscal 2009 increases 35 percent to record $4.1 billion Walgreen Co...
48 - Scarab Genomics Introduces ScarabXpress™ T7lac, a unique E. coli expression strain
MADISON, Wis.-(Business Wire)-September 29, 2009 - ScarabXpress is the latest strain in the multiple-deletion series (MDS) of Scarab Genomics Clean Genome® E. coli. Based on the MDS™42 strain, ScarabXpress T7lac contains a chromosomal copy of the T7 RNA polymerase gene expressed from a unique...
49 - Research and Markets: Turkey Pharmaceuticals and Healthcare Report Q4 2009
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets Biomeks For more information visit http://www.researchandmarkets.com/research/0423af/turkey_pharmaceuti
50 - Dynavax Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAVTM Hepatitis B Vaccine
BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot...
51 - Repros Therapeutics Inc. Provides Update on Proellex
THE WOODLANDS, Texas-(Business Wire)-September 29, 2009 - Repros Therapeutics (NasdaqGM:RPRX) today announced that the Company has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex. As announced in early August 2009, and after...
52 - PPD Announces Third Quarter 2009 Earnings Release, Webcast and Conference Call
WILMINGTON, N.C.-(Business Wire)-September 29, 2009 - PPD, Inc. (Nasdaq: PPDI) will release its third quarter 2009 financial results on Tuesday, October 27, 2009, after the market closes. The earnings release will be available on the PPD Web site at http://www.ppdi.com, FirstCall and Business...
53 - Hanford Pharmaceuticals Announces New Production Capabilities and Service Offerings
SYRACUSE, N.Y.-(Business Wire)-September 29, 2009 - On September 24, 2009, Hanford Pharmaceuticals (“Hanford” or the “Company”) completed the sale of its Cephalosporin manufacturing facility in Syracuse, NY, an asset that had been under-performing for quite some time. As part of the deal...
54 - Research and Markets: Hungary Pharmaceuticals and Healthcare Report - The Updated Q4 2009 Edition
DUBLIN-(Business Wire)-September 29, 2009 - Research and Markets For more information visit http://www.researchandmarkets.com/research/a38684/hungary_pharmaceut
55 - Maxygen Announces Management Changes
REDWOOD CITY, Calif.-(Business Wire)-September 28, 2009 - Maxygen, Inc. (Nasdaq:MAXY) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace Russell...
56 - Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility
HOUSTON-(Business Wire)-September 28, 2009 - The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management...
57 - Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference
HAYWARD, Calif.-(Business Wire)-September 28, 2009 - Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the JMP Securities Healthcare Focus Conference on Monday, October 5th, at 12:30 p.m. Eastern time. The conference will be held at The New York Palace Hotel...
58 - The Tennessee Biotechnology Association (TBA) Announces New Board Members
NASHVILLE, Tenn.-(Business Wire)-September 28, 2009 - The Tennessee Biotechnology Association: Richard Magid, PhD is Vice President at the University of Tennessee Research Foundation (UTRF) at the UT Health Science Center (UTHSC), and manages the operations of the Memphis office. This office is...
59 - Positron Exhibits at the American Society of Nuclear Cardiology Annual Conference to Promote Their Cardiac Optimized Pet Scanner
INDIANAPOLIS-(Business Wire)-September 28, 2009 - Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will attend the 14th Annual American Society of Nuclear Cardiology (ASNC) annual conference in Minneapolis, Minnesota October 1-4, 2009 to showcase...
60 - Aetna Announces Coverage For H1N1 Vaccinations
HARTFORD, Conn.-(Business Wire)-September 28, 2009 - Aetna (NYSE: AET) announced today that it will provide first-dollar coverage for the administration of the H1N1 flu vaccine for all of its fully-insured health plan members, and for all members of self-funded plans unless directed otherwise by the...
61 - Research and Markets: Algeria Pharmaceuticals and Healthcare Report Q4 2009
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets Pfizer Novartis Merck & Co Groupe Saidal For more information visit http://www.researchandmarkets.com/research/7a4e4f/algeria_pharmaceut
62 - Concentra Has Flu Shots Available to Protect Patients Against the Flu
DALLAS-(Business Wire)-September 28, 2009 - The flu season is in full swing, and health officials predict this year’s outbreak of seasonal influenza to be stronger than usual. To help protect against this highly contagious illness, Concentra is offering seasonal flu vaccines at more than 300...
63 - Catalent Pharma Solutions Appoints New Sterile Segment President, Sales and Marketing Head
SOMERSET, N.J.-(Business Wire)-September 28, 2009 - Catalent Pharma Solutions, Inc. announced today the appointment of Will Downie in a dual role as Group President, Sterile Technologies and Senior Vice President of Global Sales & Marketing, effective October 12, 2009. Mr. Downie will have...
64 - International Medica Foundation Starts Phase II Clinical Trial for Rotavirus Vaccine
ROCHESTER, Minn.-(Business Wire)-September 28, 2009 - More than half a million children – or 1,400 to 1,600 each day – die from rotavirus, the most common cause of severe childhood diarrhea. Almost all of these deaths occur in developing countries, where lifesaving medical care may not be...
65 - Research and Markets: Indonesia Pharmaceuticals and Healthcare Report Q4 2009
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets , Merck & Co, Bayer, PT Kalbe Farma, PT Bio Farma, Kimia Pharma, PT Sido Muncul, Combiphar PT For more information visit http://www.researchandmarkets.com/research/446d65/indonesia_pharmace
66 - Salix Pharmaceuticals to Present at JMP Securities Conference
RALEIGH, N.C.-(Business Wire)-September 28, 2009 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Fourth Annual JMP Securities Healthcare Focus Conference in New York, NY on Monday, October 5 at 11:30 a.m. ET. Interested parties can access a live audio...
67 - Wedgewood Pharmacy CEO Receives Highest Annual Alumni Award from Philadelphia College of Pharmacy
SWEDESBORO, N.J.-(Business Wire)-September 28, 2009 - George J. Malmberg, R.Ph., F.A.C.A., F.A.C.V.P., the pharmacist president and chief executive officer of Wedgewood Pharmacy (Swedesboro, NJ) was the 55th recipient of the Annual Alumni Award from the Philadelphia College of Pharmacy (PCP) of...
68 - Research and Markets: 2009 Has Seen a Ten-Fold Increase in the Number of Clinical Trial Using Predictive Biomarkers since 2005 Says Report 'Expanding Applications of Personalized Medicine'
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets has announced the addition of the "Expanding Applications of Personalized Medicine: Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach" report to their offering. Over the past decade, several...
69 - DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs
BIRMINGHAM, Ala.-(Business Wire)-September 28, 2009 - DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of...
70 - Sciele Pharma Submits New Drug Application to FDA for Glycopyrrolate Oral Solution, a Treatment for Chronic, Moderate-to-Severe Drooling in Pediatric Patients
ATLANTA-(Business Wire)-September 28, 2009 - Sciele Pharma, Inc., a Shionogi company, today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for glycopyrrolate oral solution to treat chronic, moderate-to-severe drooling in pediatric...
71 - Research and Markets: Morocco Pharmaceuticals and Healthcare Report - The Updated Q4 2009 Edition
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets is to be used to purchase protective masks. According to latest estimates, there have been 35 cases of swine flu in Morocco, of which 28 people have been released. Governments in the Maghreb region have responded in differing ways...
72 - Research and Markets: Argentina Pharmaceuticals and Healthcare Report - The Updated Q4 2009 Edition
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets , Sanofi-Aventis, Merck & Co, Boehringer Ingelheim, Laboratorios Roemmers, Laboratorios Bagó For more information visit http://www.researchandmarkets.com/research/3738ca/argentina_pharmace
73 - Research and Markets: Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts Through to 2015
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets has announced the addition of GlobalData 's new report "Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015" to their offering. This report is an essential source for in-depth information and data relating...
74 - Biomagnetics Diagnostics Receives a Financing Commitment up to $1 Million to Speed Development of Malaria Testing Technology
GENEVA-(Business Wire)-September 28, 2009 - Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced it has received a equity-based financing commitment up to $1 million...
75 - Ligand and GlaxoSmithKline Collaboration Identifies New Compound
SAN DIEGO-(Business Wire)-September 28, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline (NYSE:GSK), GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would...
76 - Leading Japanese CRO Attains Highest Accreditation in Medidata Solutions’ ASPire to Win Partner Program
NEW YORK & TOKYO-(Business Wire)-September 28, 2009 - Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that CMIC, one of the largest contract research organizations (CROs) in Japan, has attained Rave Accredited Plus, the...
77 - Celsion Corporation Announces $7.1 Million Registered Direct Offering
COLUMBIA, Md.-(Business Wire)-September 28, 2009 - Celsion Corporation (the “Company”) (NASDAQ: CLSN), an innovative oncology drug development company dedicated to the development and commercialization of innovative oncology drugs, today announced that it has entered into definitive agreements...
78 - RXi Pharmaceuticals to Webcast Investor Event on October 5, 2009
WORCESTER, Mass.-(Business Wire)-September 28, 2009 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will webcast its Second Annual...
79 - Hythiam Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study
LOS ANGELES-(Business Wire)-September 28, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the...
80 - Merck & Co., Inc. Obtains Exclusive U.S. Marketing Rights for AFLURIA®, Seasonal Influenza Vaccine from CSL Biotherapies
WHITEHOUSE STATION, N.J.-(Business Wire)-September 28, 2009 - Merck & Co., Inc. announced today that the Company has entered into an exclusive agreement with CSL Biotherapies, a subsidiary of CSL Limited, to market and distribute AFLURIA® (Influenza Virus Vaccine), CSL's seasonal influenza...
81 - Pappas Ventures Names Eric Linsley Managing Partner
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 28, 2009 - Pappas Ventures today announced that Eric W. Linsley has been promoted to Managing Partner. As managing partner, Linsley will play an enhanced leadership role on a team of investment, biotechnology and medical professionals who manage...
82 - PerkinElmer’s Exclusive Hyphenated Scientific Instrumentation Allows Simultaneous Testing for the Drug and Plastic Industries
SHELTON, Conn.-(Business Wire)-September 28, 2009 - PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has emerged as a leader in hyphenated scientific instrumentation with the launch of its exclusive Differential Scanning Calorimetry (DSC)-Raman...
83 - Pfizer and Composite Software to Present at EMEA Analyst Group’s BI Symposium, October 7-8, 2009
SAN MATEO, Calif.-(Business Wire)-September 28, 2009 - Composite Software, the leading provider of data virtualization software, today announced that a senior executive from Pfizer (a Composite customer) and a senior Composite executive will present at the Butler Group’s Business Intelligence (BI...
84 - MarkMonitor Finds Online Drug Brand Abuse is Growing
SAN FRANCISCO-(Business Wire)-September 28, 2009 - MarkMonitor®, the global leader in enterprise brand protection, today released the company’s latest Brandjacking Index®, which finds a parallel online system of pharmaceutical supply and demand fueled by continued growth in listings for...
85 - CSL Biotherapies Reaches Agreement with Merck & Co. on Rights to Market and Distribute Afluria® in the U.S.
KING OF PRUSSIA, Pa.-(Business Wire)-September 28, 2009 - CSL Biotherapies and its parent company, CSL Limited (ASX:CSL), one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United...
86 - Helicos Announces System Sale to Correlagen Diagnostics
CAMBRIDGE, Mass.-(Business Wire)-September 28, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis. “We are very excited to have...
87 - Halozyme Begins Clinical Trial to Compare Three Insulin Analogs and Provides Update on Ultrafast Insulin Program
SAN DIEGO-(Business Wire)-September 28, 2009 - Halozyme Therapeutics, Inc. (Nasdaq:HALO) today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase...
88 - Life Technologies and febit Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies
CARLSBAD, Calif. & HEIDELBERG, Germany-(Business Wire)-September 28, 2009 - febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted...
89 - Research and Markets: Last Report of the Year in This Series to Focus on France Pharmaceuticals and Healthcare Industry
DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets , with the latter also being developed for other indications. Sanofi-Aventis's vaccine arm Sanofi Pasteur recently signed an agreement with Delphi Genetics for the manufacture of biopharmaceuticals using the latter's StabyExpress...
90 - Inovio Biomedical to Present at Vaccine 3rd Global Congress
SAN DIEGO-(Business Wire)-September 28, 2009 - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th. Inovio...
91 - Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union
WHITEHOUSE STATION, N.J.-(Business Wire)-September 25, 2009 - Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA...
92 - Teva Provides Update on Generic Seroquel® Litigation
JERUSALEM-(Business Wire)-September 25, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 1, 2008 decision by the District Court to grant AstraZeneca’s motion for summary judgment of no inequitable...
93 - Chattem Sets Date for Third Quarter Fiscal 2009 Earnings Conference Call
CHATTANOOGA, Tenn.-(Business Wire)-September 25, 2009 - Chattem, Inc. (NASDAQ: CHTT) confirmed today that it will issue a news release regarding its third quarter and first nine months of fiscal 2009 results on Tuesday, October 6, 2009 before market open. Zan Guerry, Chairman and Chief Executive...
94 - NCPA Applauds Senate Committee’s Vote to Reduce Health Care Costs by Approving Transparency Requirements for Pharmacy Benefit Managers
ALEXANDRIA, Va.-(Business Wire)-September 25, 2009 - The National Community Pharmacists Association (NCPA) today commended the U.S. Senate Finance Committee for approving by unanimous, voice vote an amendment by U.S. Sen. Maria Cantwell (D-WA) to lower health care costs through common-sense...
95 - PCMA: Senate Finance Committee ‘Disclosure’ Amendment Will Increase Prescription Drug Costs
WASHINGTON-(Business Wire)-September 25, 2009 - Mark Merritt, President of the Pharmaceutical Care Management Association (PCMA) issued the following statement after the Senate Finance Committee’s adoption of a PBM disclosure amendment sponsored by Senator Maria Cantwell (D-Wash...
96 - Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin)
WHITEHOUSE STATION, N.J.-(Business Wire)-September 25, 2009 - Merck & Co., Inc., issued the following statement today in response to the U.S. Food and Drug Administration's (FDA's) update on JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin). "Merck has thoroughly reviewed the safety data...
97 - Positron Anticipates Cardiac PET Demand to Increase Due to Expanding Reimbursment Differential Between PET and SPECT Imaging
INDIANAPOLIS-(Business Wire)-September 25, 2009 - Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, predicts a significant rise in demand for Cardiac PET in 2010 with a proposed cut in SPECT reimbursement of 46% and an increase in PET...
98 - Research and Markets: Opportunities For Biosimilars Market Is Immense, As Biologics Worth US$25 Billion Are Going To Be Off-Patent By 2016
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets Ltd. Biopartners Cangene Cinnagen Inc. Claris Lifesciences Dong-A Pharmaceutical Dr. Reddy'S Laboratories Dsm Biologics Dynavax Technologies Emcure Genescience Pharmaceuticals Co Ltd. Gtc Biotherapeutics Ltd. Hospira Inc. Intas...
99 - Affymax Secures $60 Million Issuer Managed Equity Facility with Azimuth Opportunity, Ltd.
PALO ALTO, Calif.-(Business Wire)-September 25, 2009 - Affymax, Inc. (Nasdaq:AFFY) today announced that it has obtained an issuer managed equity facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity, Ltd. Affymax is not obligated to utilize any of...
100 - Quintiles and Allergan Announce Co-Promotion for Sanctura XR®
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 25, 2009 - Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for...
101 - Covidien Announces Dividend Increase of 12.5%
DUBLIN-(Business Wire)-September 25, 2009 - Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.16 per ordinary share to $0.18 per ordinary share. “Given our good operational performance thus far in 2009, our...
102 - Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma
CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data...
103 - Frances D. Fergusson And John P. Mascotte Elected To Pfizer’s Board Of Directors
NEW YORK-(Business Wire)-September 25, 2009 - Pfizer Inc today announced the election of Frances D. Fergusson, Ph.D. and John P. Mascotte to its Board of Directors. Dr. Fergusson and Mr. Mascotte, current members of the Board of Directors of Wyeth, will join the Pfizer Board upon the closing of...
104 - Swine Flu Vaccine Closer to Release
BALTIMORE-(Business Wire)-September 25, 2009 - The novel H1N1 virus (Swine Flu Virus) is expected to complicate the 2009/2010 flu season. The H1N1 vaccine has been approved for release but availability and access is still unknown. Seasonal influenza vaccine (flu shot) is available and the CDC...
105 - RXi Pharmaceuticals Obtains Direct Ownership of Previously Licensed RNAi Delivery Intellectual Property
WORCESTER, Mass.-(Business Wire)-September 25, 2009 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct...
106 - EnzymeRx Announces Its IND for Uricase-PEG 20 Becomes Effective
PARAMUS, N.J.-(Business Wire)-September 25, 2009 - EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become...
107 - Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801
MIRAMAR, Fla.-(Business Wire)-September 25, 2009 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its...
108 - Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference
CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare Focus...
109 - Allos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
WESTMINSTER, Colo.-(Business Wire)-September 25, 2009 - Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients...
110 - Research and Markets: This Essential Report on Distribution and Patient Support for Speciality Medicines in Europe is Now Available
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets MediService Medizorg Megapharm Mondial Assistance Movianto Pharmafreight Phoenix Polarspeed Distribution Red Swan Temperature Controlled Pharmaceuticals For more information visit...
111 - Research and Markets: The Ophthalmic Pharmaceutical Market Outlook to 2014: Competitive Landscape, Pipeline Analysis, Growth Opportunities and Market Forecasts - Now Available
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets , dry eye syndrome, ophthalmic infections and inflammation, etc.? What are the most promising ophthalmic products in clinical development and their forecast commercial potential through 2014? Which companies are best positioned to...
112 - Pfizer and Eisai Continue Aricept Collaboration
NEW YORK-(Business Wire)-September 25, 2009 - Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute...
113 - Incyte Prices $350 Million Convertible Senior Notes Offering
WILMINGTON, Del.-(Business Wire)-September 24, 2009 - Incyte Corporation (Nasdaq: INCY) today announced the pricing of its offering of $350 million aggregate principal amount of 4.75% Convertible Senior Notes due 2015 in a private placement to qualified institutional buyers pursuant to exemptions...
114 - Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock
WILMINGTON, Del.-(Business Wire)-September 24, 2009 - Incyte Corporation (Nasdaq:INCY) today announced the pricing of its underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $6.75 per share. The offering is expected to close on September 30, 2009...
115 - HealthSpring to Cover Administration Costs of H1N1 Vaccine
NASHVILLE, Tenn.-(Business Wire)-September 24, 2009 - HealthSpring will cover the costs of administering the H1N1 (swine) flu vaccination to its members as the vaccine becomes available. “We are fully supporting all government efforts for managing the H1N1 virus,” HealthSpring Chief Medical...
116 - Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions at TCT 2009
DURHAM, N.C. & SAN FRANCISCO-(Business Wire)-September 24, 2009 - Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today the transmission of a live satellite feed of a clinical case performed in the United Kingdom to an...
117 - pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009
WATERTOWN, Mass.-(Business Wire)-September 24, 2009 - pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back of the eye diseases, today announced financial...
118 - CIGNA Offers Assistance to Customers Affected by Georgia Floods
PHILADELPHIA-(Business Wire)-September 24, 2009 - CIGNA (NYSE:CI) announced today that it is temporarily lifting certain medical and pharmacy restrictions in order to aid individuals impacted by severe flooding in Georgia. People insured by CIGNA in the affected Carroll, Catoosa, Chattooga...
119 - Advaxis Cures Late Form 10-Q Filing
NORTH BRUNSWICK, N.J.-(Business Wire)-September 24, 2009 - Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, announced today that the Company's ticker symbol has been temporarily changed to ADXSE denoting untimely filing of the Company’s July 31, 2009...
120 - Medarex, Inc. Issues Notice of Change in Control to Holders of its Convertible Notes
NEW YORK-(Business Wire)-September 24, 2009 - Medarex, Inc., a wholly owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), issued, under the terms of the indenture for Medarex’s 2.25% Convertible Senior Notes due May 15, 2011 (the “Convertible Notes”), a notice of change in control...
121 - GeneWize Life Sciences, Inc., Approved As New Member of Direct Selling Association
ORLANDO, Fla.-(Business Wire)-September 24, 2009 - GeneWize Life Sciences, Inc. (“GeneWize”), subsidiary of leading consumer genomics biotech company GeneLink, Inc. (OTCBB: GNLK.OB, “GeneLink”), today announced that the Direct Selling Association (“DSA”) has approved its application...
122 - Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor...
123 - Imprime PGG® Named a Top 10 Oncology Drug Candidate for Partnering
EAGAN, Minn.-(Business Wire)-September 24, 2009 - Biothera, a privately held biotechnology company, announced today that its lead drug candidate, Imprime PGG®, has been named one of the Top 10 Most Interesting Oncology Projects Available for Partnering by Windhover Information Inc. in conjunction...
124 - The Apothecary Shops Staffs Up to Fill Erythromycin Ophthalmic Ointment Shortage in U.S. Hospitals
PHOENIX-(Business Wire)-September 24, 2009 - To offset a nationwide shortage in supplies of an ointment that protects newborn infants from contracting chlamydia and gonorrhea at birth, The Apothecary Shops is producing between 3000 and 4000 single-dose tubes a month of an erythromycin ophthalmic...
125 - Reportlinker Adds RFID in Healthcare and Pharmaceuticals 2009-2019
NEW YORK-(Business Wire)-September 24, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds RFID in Healthcare and Pharmaceuticals 2009-2019...
126 - Chao Center Donates Medications to Combat Multidrug-Resistant Tuberculosis
WEST LAFAYETTE, Ind.-(Business Wire)-September 24, 2009 - The Chao Center for Industrial Pharmacy & Contract Manufacturing officials announced that they will donate about 1,800 bottles of a medication to help fight multidrug-resistant tuberculosis (MDR-TB) to Cambodia and Ethiopia. The Chao...
127 - Priority Health to Cover Seasonal and H1N1 Flu Vaccines
GRAND RAPIDS, Mich.-(Business Wire)-September 24, 2009 - Priority Health has announced its coverage of both the seasonal flu and H1N1 flu vaccines. “Preventing the flu through immunization is the best way to keep yourself and your family healthy,” said John Fox, M.D., associate vice president of...
128 - Inhibitex Regains Compliance with NASDAQ Listing Requirements
ATLANTA-(Business Wire)-September 24, 2009 - Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a biopharmaceutical company focused on developing products to treat serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the...
129 - Reportlinker Adds EMMA09 - Emerging Markets for Microfluidic Applications
NEW YORK-(Business Wire)-September 24, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds EMMA09 - Emerging Markets for Microfluidic Applications...
130 - Synergistix President and CEO Don Schenker Named to PharmaVOICE Magazine’s 100 Most Inspiring People
SUNRISE, Fla.-(Business Wire)-September 24, 2009 - Synergistix, a leading pharma-focused customer relationship and data management company, announced today that President and CEO Don Schenker has been named to the PharmaVOICE 100, PharmaVOICE magazine’s annual list of the most inspiring and...
131 - Simbiote’s ReCES® Application Simplifies Participation in Pharmaceutical-Sponsored Research
OLIVE BRANCH, Miss.-(Business Wire)-September 24, 2009 - Simbiote Development, which develops software solutions to quantifiably improve quality of care, support risk management and strengthen revenue opportunities in physician practices, today introduced its Research Candidate Evaluation System...
132 - Reportlinker Adds Biosimilars (2009 - 2014)
NEW YORK-(Business Wire)-September 24, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Biosimilars (2009 - 2014) http://www.reportlinker.com/p0150471/Reportlinker-Adds-Biosimilars-(2009—-2014).html Report Description The...
133 - Code Corporation’s CR2500 Shown on CBS News
BLUFFDALE, Utah-(Business Wire)-September 24, 2009 - Code Corporation, an industry leader in the design and manufacturing of image-based bar code readers, was recently shown on CBS Sunday Morning News as part of a story on the government’s initiative to computerize medical records. In a 2009...
134 - Quintiles Increases Capacity to Support European Clinical Trials
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 24, 2009 - To enhance service offerings throughout Europe, Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. The purpose-built facility consolidates three buildings into a single...
135 - Research and Markets: To This End Bristol-Myers Squibb's Research to Sales Ratio Has Increased from 12.2 Per Cent in 2003, to 17.4 Per Cent in 2008
DUBLIN-(Business Wire)-September 24, 2009 - Research and Markets Isis Pharmaceuticals Lexicon Genetics Inc Medarex Inc Merck KGaA For more information visit http://www.researchandmarkets.com/research/f21dad/bristolmyers_squi Source: Espicom Business Intelligence Ltd
136 - RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease
BETHESDA, Md.-(Business Wire)-September 24, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (www.regenerx.com) announced today that it will participate in the Second International Symposium on Thymosins in Health and Disease. This conference will take place from September 30, through...
137 - Catalent and GlaxoSmithKline Extend Contractual Agreement
SOMERSET, N.J.-(Business Wire)-September 24, 2009 - Catalent Pharma Solutions and GlaxoSmithKline (GSK) have agreed to extend their contractual relationship where Catalent will continue to supply GSK with its trade requirements of Lovaza® omega-3 acid ethyl esters in soft gelatin capsules. Lovaza...
138 - Research and Markets: Nuclear Oncology Covers Imaging, Dosimetric, And Therapeutic Applications of Radiopharmaceuticals and Metabolic Imaging Agents
DUBLIN-(Business Wire)-September 24, 2009 - Research and Markets. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity...
139 - IMS Health Launches ‘Ask IMS’ to Help Early-Stage Biopharmaceutical Companies Enhance Business Development, Commercialization Strategies
NORWALK, Conn.-(Business Wire)-September 24, 2009 - IMS Health (NYSE: RX) today announced the launch of Ask IMSTM, a cost-effective, Web-based service that provides strategic market intelligence to help drive the growth and success of early-stage biopharmaceutical companies. Drawn from IMS’s...
140 - Advanced BioHealing Showcases Dermagraft at Georgetown University’s Diabetic Limb Salvage Conference
WASHINGTON-(Business Wire)-September 24, 2009 - Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, today announced that Dermagraft®, its bio-engineered skin substitute that repairs tissue damaged by disease or injury and supports the body’s...
141 - Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants at London Conference That Biomarkers Patented by His Company Promise to Revolutionize The Field of Molecular Diagnostics
SAVANNAH, Ga.-(Business Wire)-September 24, 2009 - Dr. Stephen Barnhill, Chairman and CEO, Health Discovery Corporation (OTCBB: HDVY) (“HDC”), a molecular diagnostics company, spoke at the “Biomarkers in Clinical Trials” Conference taking place in London, September 23-24, 2009. The...
142 - PHT Corporation Promotes Dwight Cooper to Vice President of Client Services
BOSTON-(Business Wire)-September 24, 2009 - PHT Corporation, the leading provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide, today announced the promotion of company executive Dwight Cooper to Vice President of Client Services. Mr. Cooper has over 15...
143 - Prime-Boost Vaccine Study Shows Modest Effect in Preventing HIV
SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 24, 2009 - Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The...
144 - The Wall Street Transcript Interviews Nutra Pharma Chairman and CEO
PLANTATION, Fla.-(Business Wire)-September 24, 2009 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J Deitsch, has been interviewed for the...
145 - Inovio Biomedical CEO Addresses MIT’s Emerging Technologies Conference
SAN DIEGO-(Business Wire)-September 24, 2009 - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, Inovio’s CEO, presented keynote remarks at MIT’s Emerging Technologies Conference hosted by the...
146 - Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL...
147 - IsoRay Inc. Announces Fiscal Year 2009 Results
RICHLAND, Wash.-(Business Wire)-September 24, 2009 - IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of lung cancer, head and neck tumors, prostate cancer and other malignant disease through use of its proprietary radioisotope technology, announces today its financial...
148 - Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
BERLIN-(Business Wire)-September 24, 2009 - Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC...
149 - Liquidia Founder Receives Prestigious NIH Director’s Pioneer Award
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 24, 2009 - Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director’s Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional...
150 - 17th Annual BioPartnering Europe™ and BioPartnering China™ Presents Innovative and Informative Program, Addressing Latest Trends Affecting the Biotech Industry Today
LONDON-(Business Wire)-September 24, 2009 - Technology Vision Group (TVG) is pleased to announce details of the program for the 17th Annual BioPartnering Europe (BPE) and BioPartnering China (BPC) conference in London from 11-14 October 2009, providing four days of networking in one location...
151 - Research and Markets: The Pharmaceutical Market in the Middle East and Africa Region is Expected to Grow at a CAGR of around 11% During 2010-2012
DUBLIN-(Business Wire)-September 24, 2009 - Research and Markets has announced the addition of the "Middle East and Africa Pharma Sector Forecast to 2012" report to their offering. The Middle East and Africa pharmaceutical industry is entering a new era, with the development of infrastructure system...
152 - Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009
SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European...
153 - Global Prostate Cancer Research Meeting Opens
SANTA MONICA, Calif.-(Business Wire)-September 24, 2009 - Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village...
154 - Helicos Announces First-Ever Direct Sequencing of Single Molecules of RNA
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the publication of a landmark study in which Helicos’ True Single Molecule Sequencing (tSMS...
155 - Rite Aid Reports Second Quarter Fiscal 2010 Results
CAMP HILL, Pa.-(Business Wire)-September 24, 2009 - Rite Aid Corporation (NYSE: RAD) today reported revenues of $6.3 billion and a net loss of $116.0 million or $.14 per diluted share for its fiscal second quarter ended August 29, 2009. Adjusted EBITDA was $216.5 million or 3.4 percent of...
156 - Nanoviricides, Inc. CEO Dr. Eugene Seymour to Address the Livingston Healthcare and Life Science Stakeholders Summit
WEST HAVEN, Conn.-(Business Wire)-September 24, 2009 - NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual Livingston Healthcare Summit on September 24th, 2009 in New York City...
157 - Pro-Pharmaceuticals to Present a Corporate Update at the Maxim Group Growth Conference
NEWTON, Mass.-(Business Wire)-September 24, 2009 - Pro-Pharmaceuticals, Inc. (OTC: PRWP) today announced that Theodore Zucconi, Ph.D., Chief Executive Officer, and James Czirr, Chairman of the Board, Pro-Pharmaceuticals, Inc., are scheduled to present a corporate update at the Maxim Group Growth...
158 - Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period
MARLBOROUGH, Mass.-(Business Wire)-September 24, 2009 - Sepracor Inc. ("Sepracor", NASDAQ: SEPR) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to the acquisition of Sepracor by Dainippon Sumitomo...
159 - The Scripps Research Institute and IAVI Host Leading Scientists Searching for New Ways to Produce an HIV/AIDS Vaccine
-(Business Wire)-September 24, 2009 - MEDIA ADVISORY: WHAT: International Symposium “Toward a Vaccine that Elicits Broadly Neutralizing Antibodies against HIV.” More than 70 leading HIV/AIDS vaccine researchers will gather to discuss recent scientific advances in the quest to develop an...
160 - Teva Provides Update on Generic Evista® Litigation
JERUSALEM-(Business Wire)-September 24, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA’s Orange Book for Eli Lilly’s Evista...
161 - Life Technologies Initiates Suit Against Illumina Alleging Patent Infringement
SAN DIEGO-(Business Wire)-September 24, 2009 - Illumina, Inc. (Nasdaq:ILMN) today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies...
162 - Emergent Health Corp. (EMGE) Announces Pending Stock Split
KING OF PRUSSIA, Pa.-(Business Wire)-September 24, 2009 - Emergent Health Corp. (Other OTC: EMGE) Emergent expects to review a stock split to increase shares for each share currently owned by existing shareholders. The final decision for the actual split ratio is expected to be made by October 31...
163 - Results of ADAGIO Study with AZILECT® in Parkinson’s Disease Published in New England Journal of Medicine
JERUSALEM-(Business Wire)-September 23, 2009 - Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson’s disease patients receiving AZILECT® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior...
164 - USIBC's ‘Coalition for Healthy India’ Releases 3(d) Report in Geneva
GENEVA-(Business Wire)-September 23, 2009 - At a roundtable organized by the Coalition for Innovation Employment and Development, the U.S.-India Business Council's 'Coalition for Healthy India' released the findings of its report on "The Value of Incremental Pharmaceutical Innovation: Benefits for...
165 - FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets
CAMBRIDGE, Mass. & VANCOUVER-(Business Wire)-September 23, 2009 - CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) in a joint meeting of its Anesthetics and...
166 - FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets
ST. LOUIS-(Business Wire)-September 23, 2009 - Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation...
167 - PCMA Urges Senate Finance Committee to Help Make Prescription Drugs More Affordable for All Americans
WASHINGTON-(Business Wire)-September 23, 2009 - Mark Merritt, President & CEO of the Pharmaceutical Care Management Association (PCMA) released the following statement regarding the Senate Finance Committee’s ongoing deliberations on health-care reform: “As the Senate Finance Committee...
168 - Purohit Navigation Engages Users in Its New Web Site
CHICAGO-(Business Wire)-September 23, 2009 - Not all healthcare agency Web sites are created equal, as Purohit Navigation’s redesigned Web site (purohitnavigation.com) demonstrates. To engage visitors to the Web site immediately, Purohit Navigation has strategically used animation and design to...
169 - Research and Markets: Gilead Sciences: Pipeline - Products - Performance - Potential
DUBLIN-(Business Wire)-September 23, 2009 - Research and Markets OPERATIONAL DATA A wealth of background and detail A full 5-year financial performance assessment Key corporate events Key agreements Infrastructure Subsidiaries and joint ventures Companies Mentioned: 4AZA Bioscience Achillion...
170 - UnitedHealth Group Authorizes Early Prescription Refills and Opens Free Counseling Help Line for People in Flood-Affected Counties in Georgia
MINNETONKA, Minn.-(Business Wire)-September 23, 2009 - UnitedHealth Group (NYSE: UNH) and its family of companies are authorizing plan participants who are affected by the floods in Georgia and enrolled in its fully insured health plans and pharmacy benefit management (PBM) services to obtain...
171 - PsoriasisDX and HairDX To Present “Pharmacogenomics In Dermatology And Cosmetics” During EADV Congress
BERLIN & IRVINE, Calif.-(Business Wire)-September 23, 2009 - A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the...
172 - BioPharm America™ 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US
CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Over 700 leaders from the biotechnology and pharmaceutical industry gathered last week for the 2nd annual BioPharm America™ partnering conference, which saw delegates from 665 companies engage in 1579 one-to-one partnering...
173 - Walgreens to Compound Tamiflu Oral Suspension for Children in Response to Supply Shortage
DEERFIELD, Ill.-(Business Wire)-September 23, 2009 - Less than a month after launching the largest flu prevention initiative in the company’s 108-year history, Walgreens (NYSE: WAG)(NASDAQ: WAG) is taking proactive measures to ensure its nearly 7,000 pharmacies can provide the suspension - or...
174 - BioVectra Announces Oncolix Inc. Signs Manufacturing and Investment Agreement
CHARLOTTETOWN, PEI-(Business Wire)-September 23, 2009 - BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PEI, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for...
175 - LifeSensors, Inc. Obtains Worldwide, Exclusive License to High Affinity “Ubiquitin Traps”
MALVERN, Pa.-(Business Wire)-September 23, 2009 - LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed...
176 - European Commission Grants Conditional Marketing Authorization to Cayston® (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis
FOSTER CITY, Calif.-(Business Wire)-September 23, 2009 - Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of...
177 - Celladon's MYDICAR® and Small Molecule SERCA2a Studies in Acute and Chronic Heart Failure Selected as One of Windhover’s Top 10 Cardiovascular Programs to Watch
SAN DIEGO-(Business Wire)-September 23, 2009 - Celladon Corporation today announced that its SERCA2a programs for the treatment of patients with acute and chronic heart failure have been chosen by Windhover and an independent expert panel as one of the top 10 most interesting cardiovascular projects...
178 - MicroDose Therapeutx Announces Initiation of Phase 1 Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning
MONMOUTH JUNCTION, N.J.-(Business Wire)-September 23, 2009 - MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has initiated a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder...
179 - MSGI Announces First Nanobeak Product -- Handheld Bloodless Diabetes Test
NEW YORK-(Business Wire)-September 23, 2009 - MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood. Nanobeak Inc., an MSGI subsidiary, is a...
180 - For Sixth Consecutive Year, Pfizer Earns Highest Score In Human Rights Campaign Foundation LGBT Ranking
NEW YORK-(Business Wire)-September 23, 2009 - Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors...
181 - pSivida Anounces New Iluvien® Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion
WATERTOWN, Mass.-(Business Wire)-September 23, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease...
182 - Research and Markets: Forest Laboratories: Pipeline - Products - Performance - Potential
DUBLIN-(Business Wire)-September 23, 2009 - Research and Markets have a combined forecasted sales total of US$1,085.4 million for fiscal 2013, which is around half the sales Lexapro is currently generating. The acquisition of Cerexa provides Forest with major opportunities in an entirely new...
183 - KIKA Clinical Solutions Announces Veracity™ 3.7, New Version of Advanced EDC Solution for Clinical Trial Management
BOSTON & PARIS-(Business Wire)-September 23, 2009 - KIKA Clinical Solutions, the leading provider of advanced EDC solutions for clinical trials, continues leading the industry in providing solutions that go well beyond traditional EDC with the release of Veracity™ 3.7. Veracity™ is a...
184 - First-Ever Controlled Pharmacological Study of ADHD in College Students Launched
BETHLEHEM, Pa.-(Business Wire)-September 23, 2009 - In an effort to help one of the most under studied groups of sufferers of attention deficit hyperactivity disorder (ADHD), researchers at University of Rhode Island and Lehigh University have kicked off the first-ever controlled pharmacological...
185 - Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries
NEW YORK-(Business Wire)-September 23, 2009 - Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world. This initiative is the first time a vaccine...
186 - NCPDP Appoints Stephen Mullenix Senior Vice President of Communications and Industry Relations
SCOTTSDALE, Ariz.-(Business Wire)-September 23, 2009 - The National Council for Prescription Drug Programs (NCPDP), a not-for-profit pharmacy standards development organization, announced the recent appointment of Stephen C. Mullenix, R. Ph., as its Senior Vice President of Communications and...
187 - Advanced BioHealing Outlines Strategic Growth Plan
WESTPORT, Conn.-(Business Wire)-September 23, 2009 - Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative...
188 - Genzyme Provides Update on Cerezyme and Fabrazyme Supply
CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these...
189 - Health Net Shares Medication Safety Tips
LOS ANGELES-(Business Wire)-September 23, 2009 - The beginning of October marks the start of Talk About Prescriptions Month, which is sponsored by the National Council on Patient Information and Education. In support of this annual awareness effort, Health Net, Inc. (NYSE:HNT) is sharing tips to...
190 - Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
BERLIN-(Business Wire)-September 23, 2009 - According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent-to-treat (ITT) population of first-line metastatic...
191 - Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye
JERSEY CITY, N.J.-(Business Wire)-September 23, 2009 - Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class...
192 - Philips and Celsion Advance Development of ThermoDox® and MR-Guided HIFU
ANDOVER, Mass. & COLUMBIA, Md.-(Business Wire)-September 23, 2009 - Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High...
193 - Opexa Triggers Milestone Payment Under Recently Announced Stem Cell Agreement
THE WOODLANDS, Texas-(Business Wire)-September 23, 2009 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the...
194 - Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers
SUNNYVALE, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today positive results from three multicenter first-in-man studies of NovolimusTM...
195 - Research and Markets: The Evolving Pharma M&A Landscape: Emerging Trends and Predicted Post-Blockbuster Targets - Now Available
DUBLIN-(Business Wire)-September 23, 2009 - Research and Markets has announced the addition of the "The Evolving Pharma M&A Landscape: Emerging Trends and Predicted Post-Blockbuster Targets" report to their offering. Pharmaceutical market growth rates have halved inside the past five years...
196 - Eldorado and WellDyneRx Announce Strategic Alliance
PHOENIX-(Business Wire)-September 23, 2009 - Eldorado Computing, Inc. (ELDORADO), a leading provider of health benefit and claims management platforms, and WellDyneRx Inc., a national pharmacy benefits management (PBM) company, announced today that they are collaborating to create and market...
197 - CombinatoRx Stock Trading Halted Today; FDA Advisory Committees Meet to Discuss Exalgo
CAMBRIDGE, Mass. & VANCOUVER-(Business Wire)-September 23, 2009 - CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today. The U.S. Food and Drug Administration’s (FDA) Anesthetics and Life Support Advisory Committee and its...
198 - Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
HAIFA, Israel-(Business Wire)-September 23, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment...
199 - Humedica’s Next-Generation Clinical Informatics Platform Offers Unparalleled Insight across the Health Care Continuum
BOSTON-(Business Wire)-September 23, 2009 - Humedica, a next-generation health care informatics company, today announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and the roll-out of its ground-breaking clinical analytics...
200 - Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva® and Avastin® in Non-Small Cell Lung Cancer
CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small...
Search Our News Using Google Search
Can't find what you want? Try using Google:
